Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

Renáta Váraljai ,

Lisa Zimmer ,

Yahya Al-Matary ,

Paulien Kaptein ,

Lea J Albrecht ,

Batool Shannan ,

Jan C Brase ,

Daniel Gusenleitner ,

Teresa Amaral ,

Nina Wyss ,

Jochen Utikal ,

Lukas Flatz ,

Florian Rambow ,

Hans Christian Reinhardt ,

Jenny Dick ,

Daniel R Engel ,

Susanne Horn ,

Selma Ugurel ,

Wiebke Sondermann ,

Elisabeth Livingstone ,

Antje Sucker ,

Annette Paschen ,

Fang Zhao ,

Jan M Placke ,

Jasmin M Klose ,

Wolfgang P Fendler ,

Daniela S Thommen ,

Iris Helfrich ,

Dirk Schadendorf ,

Alexander Roesch

More about this publication

Nature cancer

Volume 4

Issue nr. 9

Pages 1395

Publication date 01-09-2023

Full text links

Publisher website (DOI) 10.1038/s43018-023-00632-w

Europe PubMed Central 37580519

Pubmed 37580519